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Abstract The present study investigates the effects of the
ﬁrst mutation of troponin C (hcTnC
L29Q) found in a patient
with hypertrophic cardiomyopathy (HCM) on force–pCa
relations and the interplay with phosphorylation of sarco-
meric PKA substrates. In triton-skinned murine cardiac
ﬁbers, the endogenous mcTnC was extracted and the ﬁbers
weresubsequentlyreconstitutedwithrecombinantwild-type
and mutant hcTnC. Force–pCa relations of preparations
containinghcTnC
L29QorhcTnC
WTweresimilar.Incubation
of ﬁbers reconstituted with the recombinant proteins with
phosphatase to dephosphorylate sarcomeric PKA substrates
induced an increase in Ca
2? sensitivity, slightly more pro-
nounced (0.04 pCa units) in hcTnC
L29Q-containing ﬁbers.
IncubationofthedephosphorylatedﬁberswithPKAinduced
signiﬁcant rightward shifts of force–pCa relations of similar
magnitude with both, hcTnC
L29Q and hcTnC
WT. No signi-
ﬁcant effects of hcTnC
L29Q on the velocity of unloaded
shortening were observed. In conclusion, no major differ-
ences in contractile parameters of preparations containing
hcTnC
L29Q compared to hcTnC
WT were observed.
Therefore, it appears unlikely that hcTnC
L29Q induces the
development of HCM by affecting the regulation of Ca
2?-
activated force and interference with PKA-mediated modu-
lation of the Ca
2? sensitivity of contraction.
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Protein kinase A  Hypertrophic cardiomyopathy
Introduction
Cardiac troponin C (cTnC) is the Ca
2?-binding subunit of
the heterotrimeric troponin complex (cTn), which further
consists of the inhibitory subunit, troponin I (cTnI), and the
tropomyosin binding subunit, troponin T (cTnT), and is
essential in initiating contraction of the heart. As an
EF-hand protein, cTnC consists of an N-terminal and a
C-terminal lobe, which each contain two metal-binding
sites. In cardiac muscle only the reversible Ca
2? binding to
a single site, the regulatory site II in the N-terminal lobe of
cTnC (cNTnC), is essential for the regulation of contrac-
tion, while regulatory site I is non-functional, however, its
amino acid composition may inﬂuence the Ca
2?-binding
properties of site II [17, 28]. Sites III and IV of the
C-terminal lobe are permanently metal-bound under
physiological conditions and are thought to serve a
structural function (reviewed in [22]).
During the systolic elevation of cytosolic Ca
2?,C a
2?
binding to the regulatory site II of cTnC opens a hydro-
phobic pocket in cNTnC, thereby exposing strong inter-
action sites for the switch peptide of cTnI (*residues
147–163). This interaction pulls the inhibitory region of
cTnI (*residues 128–147) away from its binding site on
actin, allowing strong binding of myosin crossbridges to
actin and thus providing the basis for Ca
2?-induced cardiac
A. Neulen (&)  R. Stehle  G. Pﬁtzer (&)
Institute of Vegetative Physiology, University of Cologne,
Robert-Koch-Strasse 39, 50931 Cologne, Germany
e-mail: Axel.Neulen@uni-koeln.de;
Axel.Neulen@med.uni-goettingen.de
G. Pﬁtzer
e-mail: Gabriele.Pﬁtzer@uni-koeln.de
A. Neulen
Department of Neurosurgery, Georg August University,
Robert-Koch-Strasse 40, 37099 Go ¨ttingen, Germany
R. Stehle  G. Pﬁtzer
Center of Molecular Medicine, University of Cologne,
Robert-Koch-Strasse 39, 50931 Cologne, Germany
123
Basic Res Cardiol (2009) 104:751–760
DOI 10.1007/s00395-009-0038-ycontraction (reviewed in [22]). Speciﬁc to the heart, the
‘‘open’’ conformation is stabilized by binding of the N-
terminal arm of cTnI (residues 16–29) to cNTnC [42]. This
interaction is weakened by PKA-mediated phosphorylation
of Ser23/24 of cTnI giving rise to the well-known decrease
in Ca
2? sensitivity of actomyosin interaction and contrac-
tion which is thought to contribute to the lusitropic effect of
b-adrenergic receptor stimulation (reviewed in [26 and
references therein; 30]). Given the prominent role cTnC
plays in the regulation of cardiac contraction, it is intui-
tively apparent that an impaired function of cTnC will
likely lead to inefﬁcient regulation of contraction and
subsequently to systolic or diastolic dysfunction which may
result in cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is considered to
be the most frequent inherited disease of the myocardium
and thought to be caused by point mutations in genes
encoding proteins of the cardiac sarcomere (reviewed in
[39]). More recently it was also recognized that about 30%
of idiopathic dilated cardiomyopathies can be ascribed to
mutations of sarcomeric proteins (reviewed in [1]). How-
ever, despite the fact that, in many sarcomeric proteins, a
large number of HCM- or DCM-linked mutations were
found, relatively few mutations were found so far in human
cTnC [4, 21, 25, 31]. Whereas HCM is characterized by
diastolic dysfunction and normal systolic function [29],
DCM is characterized by systolic dysfunction [6]. The
tendency of HCM-linked mutations in cTn subunits to
increase and of DCM-linked mutations to decrease the
Ca
2? sensitivity of contraction [9, 38] may reﬂect the fact
that sarcomeric processes contribute to impaired relaxation
(HCM) or contraction (DCM) of the myocardium.
The HCM-associated mutation hcTnC
L29Q was found in
a 60-year-old male patient who presented with dyspnea on
exertion and echocardiographic examination revealed a
concentric hypertrophy of the left ventricle [21]. Leu-29 is
located at the transition of helix A to the non-functional
Ca
2?-binding site I. Amino acid substitutions in this region
may impact on the structure and the Ca
2? afﬁnity of site II
of cNTnC. Indeed, in cold water ﬁsh, the L29Q substitution
belongs to a series of amino acid exchanges that increase
Ca
2? sensitivity of the heart at low temperatures [10].
Further, L29Q is located adjacent to the residues which
bind to the non-phosphorylated N-terminal arm of cTnI.
Studies with isolated proteins indicate that the mutation
interferes with binding of the N-terminal arm of cTnI to
cNTnC, which in effect would mimic the modulatory effect
of cTnI phosphorylation at Ser23/24 on Ca
2? activation [4,
13, 35]. These studies give rise to the interesting possibility
that the mutation will alter Ca
2? activation and affect the
functional transduction of PKA-dependent phosphorylation
of cTnI to Ca
2?-activated force; however, functional
studies yielded highly contradictory results as to its effects
on Ca
2?-dependent force and on acto-S1 ATPase activity
[15, 28, 35].
The effects of PKA-mediated phosphorylation of cTnI
are critical for the response of the heart to b-adrenergic
stimulation, and alterations in the beta-adrenergic response
are thought to be a major mechanism contributing to the
pathogenesis of heart failure [40, 41]. In accordance with
the structural studies [4, 13, 35] the modulatory effect of
cTnI phosphorylation by PKA on the Ca
2? sensitivity of
acto-S1 MgATPase activity and of sliding velocity of actin
ﬁlaments in the in vitro motility assay was abrogated [35].
However, it remains unknown whether the PKA-induced
decrease in Ca
2? sensitivity of contraction is affected in the
myoﬁlament lattice of myoﬁbrils.
The aim of the present study was therefore to investigate
the effect of recombinant hcTnC
L29Q on isometric force
and on unloaded shortening velocity of triton-skinned
myocardium. Such preparations are devoid of functional
cell membranes and a functional sarcoplasmatic reticulum,
while the myoﬁlament lattice of the myoﬁbrils remains
structurally intact. Biochemical exchange protocols allow
to incorporate recombinant troponin subunits into the
cardiac sarcomeres [12, 15, 28]. In particular, we investi-
gated whether the mutation abrogates the PKA-induced
decrease in Ca
2? sensitivity of contraction in myoﬁbrils by
dephosphorylating skinned ﬁbers containing hcTnC
L29Q
with the catalytic subunit of Mn
2?-PP1c and rephosphory-
lating them with PKA [33].
Materials and methods
Skinned cardiac ﬁbers
The ‘‘Principle of laboratory animal care’’ (NIH publica-
tion No. 86–23, revised 1985) were followed, and the study
was approved by the responsible Animal Care and Use
Committee. Adult male mice of the strain HIM:OF1 were
sacriﬁced by cervical dislocation. The hearts were removed
and immediately transferred to ice-cold preparation buffer
containing 132 mM NaCl, 5 mM KCl, 1 mM MgCl2,
10 mM Tris, 5 mM EGTA, 1 mM NaN3, pH 7.1 (20C).
Fibers of a diameter of *200 lm were prepared on ice
from left ventricular papillary muscles. For skinning, the
ﬁbers were ﬁxed isometrically and incubated in skinning
solution on ice for 4 h. The skinning solution contained
5m MK H 2PO4, 5 mM NaN3, 3 mM magnesium acetate,
5m MK 2EGTA, 3 mM Na2MgATP, 47 mM sodium cre-
atine phosphate, 2 mM dithiothreitol (DTT), 0.2 mM 4-(2-
aminoethyl)benzenesulfonyl-ﬂuoride (AEBSF), 10 lM
leupeptin, 10 lM antipain, 5 mg/l aprotinin, and 1% (m/v)
Triton X-100. After skinning, the ﬁbers were stored on ice
in skinning solution without Triton X-100 over night.
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Activating and relaxing solution contained either 3 mM
(Ca)K2EGTA (activating solution) or 3 mM K2EGTA
(relaxing solution), 10 mM imidazole, 10 mM Na2M-
gATP, 3 mM MgCl2, 32.7 mM sodium creatine phos-
phate, 2 mM DTT, pH 7.0 (10C), l = 178 mM. Skinned
ﬁbers were mounted between a force transducer (KG7A
with bridge-ampliﬁer DUBAM 7C, Scientiﬁc Instruments,
Heidelberg) and a ﬁxed clamp in skinning solution
without Triton X-100 and pre-stretched by 10% of their
initial length. Before recording force–pCa relations, a test
contraction was elicited in activating solution (pCa 4.6).
The ﬁbers were then transferred to relaxing solution (pCa
8). Force–pCa relations were recorded by incubating the
ﬁbers in solutions with cumulatively rising Ca
2?
concentrations which were mixed from activating and
relaxing solutions, and pCa50 (pCa required for half-
maximal tension) and nH (Hill coefﬁcient) were calcu-
lated by ﬁtting the data to the Hill equation as described
[36]. Unless noted otherwise, the experiments were per-
formed at 10C controlled by thermo-electric coolers to
preserve the structural integrity of ﬁbers during activation
[36].
Unloaded shortening velocity
After mounting, the preparations were pre-stretched by
10% of their initial length. The ﬁbers were activated (pCa
4.6) at 10C and force was allowed to stabilize for
*5 min. Unloaded shortening velocities were determined
with two different methods using a commercial setup
(Scientiﬁc Instruments, Heidelberg, Germany):
1. Force–velocity relations were recorded using the
technique of isotonic load clamping: brieﬂy, shorten-
ing velocities were recorded at constant loads clamped
to values between 5 and 30% of the force during
activation. The unloaded shortening velocity (VMAX)
was calculated for each preparation according to Hill
[20] using Sigma Plot 4.0 (Systat Software Inc.,
Richmond, California, USA).
2. Unloaded shortening velocities were determined using
the ‘‘Edman slack test’’ [16]: brieﬂy, a series of nine
releases (ramp time *1 ms) of an amplitude between
12 and 17% of the ﬁber length was applied onto the
preparation. The ﬁber was stretched back to its initial
length 0.2 s after each release. Force was monitored
continuously during this procedure. The duration of
unloaded shortening was determined for each release,
and the velocity of unloaded shortening was calculated
according to Edman [16] using Sigma Plot 4.0 (Systat
Software Inc.).
Extraction of endogenous troponin C and reconstitution
with recombinant human cardiac troponin C
Recombinant human cardiac troponin C (hcTnC
L29Q and
hcTnC
WT) was generously provided by K. Jaquet
(Bochum, Germany). For extraction of endogenous mur-
ine cTnC (mcTnC) and reconstitution with hcTnC, the
method of Dohet et al. [12] was modiﬁed (cf. Fig. 1). The
complete procedure was performed at 10C. Skinned
ﬁbers were incubated for 10 min in buffer 1 containing
10 mM imidazole, 2.5 mM EGTA, 7.5 mM EDTA,
135 mM potassium propionate, pH 6.8 (20C). After this,
the ﬁbers were incubated for 180 min in extraction buffer
containing 0.1 mM triﬂuoperazine, 2 mM trans-1,2-
diaminocyclohexane-N,N,N,N-tetraacetic acid (CDTA),
2 mM imidazole, 1 mM NaN3, 2 mM DTT, 0.5 mM
AEBSF, 0.01 mM leupeptin, 0.01 mM antipain, 5 mg/l
aprotinin, pH 7.4 (20C). Then the ﬁbers were equili-
brated in relaxing solution for 5 min. To check the
efﬁciency of mcTnC extraction, the ﬁbers were Ca
2?-
activated (pCa 4.6) for 15 min. Only ﬁbers which did not
develop force in activating solution any more were used
for cTnC reconstitution and incubated in relaxing solution
containing either 2 g/l hcTnC
L29Q or hcTnC
WT for
60 min. Following reconstitution with recombinant
hcTnC, force–pCa relations or unloaded shortening were
measured as described above either directly, or after
pCa  8  4.5 8 8 4.5  8   8 4.5    8
 B1, EB   hcTnC
0
.
3
m
N
12 min 12 min 12 min
60 min 60 min
Fig. 1 Force transient recorded during cTnC extraction and recon-
stitution. Maximal Ca
2?-activated force (FMAX) is determined at pCa
4.6, then mcTnC is extracted by incubation in ‘‘buffer 1’’ and
extraction buffer (B1, EB, see methods). Ca
2?-activated force is lost
after 180 min incubation in EB. Following reconstitution with
recombinant hcTnC Ca
2?-dependent force is partially restored
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phosphorylation.
Phosphatase treatment
Phosphatase treatment was performed as described [33].
Brieﬂy, skinned ﬁbers were equilibrated for 10 min at 10C
with PP1c buffer containing 20 mM Na2MnATP, 3 mM
MnCl2, 3 mM K2EGTA, 10 mM imidazole, 5 mM MgCl2,
10 mM sodium creatine phosphate and 2 mM DTT, pH
6.85 (20C), followed by incubation in the same buffer
with 0.5 kU/ml PP1c (Sigma, Deisenhofen, Germany) at
10C for 90 min. Following PP1c treatment the ﬁbers were
incubated in relaxing solution containing 50 mM DTT at
20C for 30 min.
PKA phosphorylation
Recombinant human catalytic subunit (C-subunit) of PKA
(14 MU/ml, generously provided by K. Jaquet, Bochum,
Germany) was stored at 4C in 1 mM EDTA, 2 mM DTT,
5m Mb-mercaptoethanol, 150 mM K2HPO4/KH2PO4,p H
6.5 [19]. The C-subunit was diluted in relaxing solution to
give a ﬁnal activity of 0.5 MU/ml. The ﬁbers were incu-
bated in this solution at 20C for 60 min. Control ﬁbers
were subjected to the same protocol with appropriate
control buffer (PKA buffer) without C-subunit. Phosphory-
lation was veriﬁed by incubating ﬁbers with PKA in the
presence of [c
32P]-ATP and autoradiography using X-ray
ﬁlms as described [33].
Statistics
All data were calculated using SIGMA PLOT 4.0 (Systat
Software Inc., Richmond, California, USA) and are given
as mean ± SEM. ‘‘n’’ in ﬁgures and tables refers to
the number of animals. Differences among groups was
tested by Student’s t-test or one way ANOVA and
Newman–Keuls test as post-test using graph pad soft-
ware, a P value \0.05 was considered as statistically
signiﬁcant.
Results
Effect of hcTnC
L29Q on isometric force
To assess the effect of the hcTnC
L29Q mutation on Ca
2?-
activated steady state force and on shortening velocity,
endogenous murine cardiac troponin C (mcTnC) was
extracted from skinned ﬁbers by incubation in extraction
buffer for 3 h followed by reconstitution with either wild-
type or mutant hcTnC. Incubation in extraction buffer
induced a complete loss of Ca
2?-dependent force in acti-
vating solution (pCa 4.6, see Fig. 1). Ca
2?-regulated force
recovered after reconstitution of the ﬁbers in relaxing
solution containing recombinant hcTnC. However, as
reported by others [3, 12, 15, 28], maximal Ca
2?-activated
force (pCa 4.6) in the reconstituted ﬁbers was reduced
(Fig. 1), which was similar in ﬁbers exchanged for
hcTnC
WT or hcTnC
L29Q (Fig. 2; Table 1).
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Fig. 2 Force–pCa relations of
ﬁbers reconstituted with
hcTnC
L29Q or hcTnC
WT. Force–
pCa relations were measured
before extraction of mcTnC
(dashed lines, open circle) and
after reconstitution with
hcTnC
L29Q (a) or hcTnC
WT (b),
respectively (solid lines, open
triangle). Symbols represent
mean ±SEM for n = 6
preparations
Table 1 Contractile parameters of skinned ﬁbers before mcTnC extraction and after reconstitution with hcTnC
L29Q or hcTnC
WT
Passive force (%) FMAX (%) pCa50 nH
L29Q, before mcTnC extraction 2.9 ± 0.5 100 5.47 ± 0.02 4.71 ± 0.19
L29Q, after reconstitution 2.5 ± 0.4 60 ± 2*** 5.40 ± 0.01 4.49 ± 0.18
WT, before mcTnC extraction 3.0 ± 0.4 100 5.50 ± 0.02 4.65 ± 0.33
WT, after reconstitution 3.2 ± 0.4 64 ± 3*** 5.44 ± 0.03 4.33 ± 0.33
Data are given as mean ± SEM, n = 6, passive force was measured at pCa 8.0 and FMAX (maximal force) at pCa 4.6. Passive force and FMAX
were normalized to FMAX of the ﬁrst force–pCa relation
*** P\0.001
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relation, a full force–pCa relation was obtained before
extraction and after reconstitution. Thus, each ﬁber served
as its own control. As a measure of Ca
2? sensitivity the
pCa50 value, and as a measure of cooperativity the Hill
coefﬁcient was calculated for each curve. Before extrac-
tion, the force–pCa relations were similar between ﬁbers to
be exchanged for either wild-type or mutant hcTnC. Fol-
lowing reconstitution, the Ca
2? sensitivity slightly
decreased by a similar extent in both cases, which did not
reach the level of statistical signiﬁcance (Fig. 2; Table 1).
The shifts in pCa50 were calculated for each ﬁber, giving
similar results for the exchange procedure with hcTnC
L29Q
or hcTnC
WT (cf. Table 4). The steepness of the force–pCa
relation, which is indicative of the cooperativity, was not
signiﬁcantly different between hcTnC
L29Q- and hcTnC
WT-
containing ﬁbers (Fig. 2; Table 1). Passive force, i.e. force
in the absence of Ca
2?, also remained similar in ﬁbers
exchanged with wild-type or mutant hcTnC (Figs. 2, 3, 4;
Tables 1, 2, 3).
Effect of hcTnC
L29Q on isometric force after treatment
with phosphatase and PKA
We have previously shown that, in triton-skinned murine
cardiac ﬁbers, sarcomeric PKA substrates are phosphory-
latedinafunctionallyrelevantmanner[24,33],whichmeans
that hcTnC
L29Q and hcTnC
WT were exchanged into ﬁbers
containing phosphorylated cTnI. This may inﬂuence the
effect of the mutation on the force–pCa relation [4, 14, 35].
We previously reported [24, 33] that the commercially
available Mn
2?-dependent catalytic subunit of PP1c which
has a different substrate speciﬁcity than the type 1 phos-
phatases can be used as a tool to dephosphorylated these
proteins.Toverify thatcTnI intheﬁbersofthepresent study
was phosphorylated, ﬁbers were incubated with or without
PP1c and then treated with PKA in the presence of [c
32P]-
ATP. Similar to our previous study [33], PKA incorporated
*twofold more
32P into cTnI after pretreatment with
phosphatase (Fig. 3). We note, that in the present series of
experiment,
32P incorporation into cMyBP-C is less than in
our previous report [33] which is probably due to the lower
speciﬁc activity of [c
32P]-ATP used here as detection of
32P
incorporation into cMyBP-C requires a higher speciﬁc
activity (unpublished observations). It remains unknown
whether PP1c treatment also dephosphorylates other pro-
teins;however,itisunlikelythatdephosphorylationofPKA-
independentsitescontributestothePP1c-inducedchangesof
the force–pCa relation because PKA quantitatively reverses
the effect of PP1c [33].
In both, hcTnC
L29Q- or hcTnC
WT-exchanged ﬁbers,
treatment with Mn
2?-dependent catalytic subunit of PP1c
Fig. 3 Dephosphorylation of PKA targets by Mn
2?-dependent PP1c.
Fibers were either treated or not treated with PP1c and then incubated
with PKA in the presence of [c
32P]-ATP as in [32]. Lysates were
subjected to SDS-PAGE. Gels were Coomassie-stained, dried, and
exposed to X-ray ﬁlms.
32P incorporation into cTnI was enhanced by
*twofold in ﬁbers pretreated with PP1c
Fig. 4 Phosphatase and PKA treatment of cTnC-exchanged ﬁbers.
Force–pCa relations were measured before extraction of endogenous
mcTnC (dashed lines, open triangle) and after reconstitution with
hcTnC
L29Q (a) or hcTnC
WT (b) and treatment with PP1c (solid lines,
open circle). After phosphatase treatment, the pCa50 values were not
signiﬁcantly different between ﬁbers reconstituted with hcTnC
L29Q or
hcTnC
WT, respectively. Symbols represent mean ±SEM for n = 5
preparations. After phosphatase treatment, PKA was added (dotted
lines, open square), resulting in signiﬁcant rightward shifts of the
force–pCa relations of similar magnitude. Symbols represent mean
±SEM for n = 3 preparations
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2? sensitivity. Passive force
and pCa50 increased and nH slightly decreased compared to
the force–pCa relations before mcTnC extraction, while the
reduction of maximal force was similar to the ﬁbers not
treated with phosphatase (see Fig. 4; Table 2). The
increase in Ca
2? sensitivity was more pronounced in ﬁbers
exchanged for hcTnC
L29Q compared to the ﬁbers exchan-
ged for hcTnC
WT (DpCa50 = 0.04 pCa units; see Tables 2,
4). However, this difference did not reach the level of
statistical signiﬁcance.
In a reconstituted system, the PKA-induced decrease in
Ca
2? sensitivity of acto-S1 ATPase activity was abrogated
by the mutation [35]. To investigate whether in hcTnC
L29Q-
exchangedskinnedﬁbersthePKA-induceddecreaseinCa
2?
sensitivity on contraction is also lost (cf. [35]), the phos-
phatase-treated ﬁbers were incubated with PKA. As previ-
ously reported [33], this resulted in a signiﬁcant rightward
shift of the force–pCa relation of similar magnitude in both,
ﬁbers exchanged with hcTnC
L29Q (DpCa50 = 0.20 pCa
units) and hcTnC
WT (DpCa50 = 0.18 pCa units; cf. Fig. 4;
Tables 3, 4), whereas no signiﬁcant changes were observed
after incubation with PKA buffer only (data not shown).
Hence, hcTnC
L29Q does not blunt the PKA-induced
Ca
2?-desensitization of force.
Effect of hcTnC
L29Q on the velocity of unloaded
shortening
To investigate whether hcTnC
L29Q affects the velocity of
unloaded shortening at high [Ca
2?], endogenous mcTnC
was extracted and force reconstituted with either
hcTnC
L29Q or hcTnC
WT as above. The velocity of unloa-
ded shortening was determined before and after extraction
of mcTnC and reconstitution with hcTnC
L29Q or hcTnC
WT
from load–velocity relations. After reconstitution, the
velocity of unloaded shortening was reduced by 37%
(hcTnC
L29Q) or 35% (hcTnC
WT) compared to unloaded
shortening before mcTnC extraction (see Fig. 5). These
ﬁndings were conﬁrmed by data from the ‘‘Edman slack
test’’. Here, the velocity of unloaded shortening was
reduced by 37% (hcTnC
L29Q) or 39% (hcTnC
WT, see
Fig. 5). In summary, hcTnC
L29Q compared to hcTnC
WT did
not inﬂuence the velocity of unloaded shortening in a
signiﬁcantly different way.
Discussion
L29Q was the ﬁrst mutation of cTnC described in one
patient with hypertrophic cardiomyopathy and no available
Table 2 Contractile parameters of skinned ﬁbers before mcTnC extraction and after reconstitution with hcTnC
L29Q or hcTnC
WT and incubation
with phosphatase
Passive force (%) FMAX (%) pCa50 nH
L29Q, before mcTnC extraction 2.8 ± 0.6 100 5.48 ± 0.02 5.45 ± 0.02
L29Q, after reconstitution, PP1c 4.2 ± 0.7** 69 ± 3*** 5.55 ± 0.03 4.16 ± 0.37*
WT, before mcTnC extraction 3.4 ± 1.0 100 5.47 ± 0.02 5.56 ± 0.78
WT, after reconstitution, PP1c 4.0 ± 0.6 66 ± 1*** 5.50 ± 0.03 4.59 ± 0.27
Data are given as mean ± SEM, n = 5, passive force was measured at pCa 8.0 and FMAX (maximal force) at pCa 4.6. Passive force and FMAX
were normalized to FMAX of the ﬁrst force–pCa relation
* P\0.05, ** P\0.01, *** P\0.001
Table 3 Contractile parameters of skinned ﬁbers after reconstitution
with hcTnC
L29Q or hcTnC
WT and incubation with phosphatase, and
after following treatment with PKA
Passive
force (%)
FMAX
(%)
pCa50 nH
L29Q, after
reconstitution,
PP1c
4.0 ± 0.9 63 ± 5 5.53 ± 0.03 4.38 ± 0.44
?PKA 3.7 ± 1.1 59 ± 5 5.34 ± 0.02*** 4.67 ± 0.24
WT, after
reconstitution,
PP1c
5.2 ± 0.5 65 ± 2 5.53 ± 0.05 4.56 ± 0.39
?PKA 4.2 ± 1.1 60 ± 4 5.35 ± 0.05*** 5.10 ± 0.56
Data are given as mean ± SEM, n = 3, passive force was measured
at pCa 8.0 and FMAX (maximal force) at pCa 4.6. Passive force and
FMAX were normalized to FMAX of the ﬁrst force–pCa relation
*** P\0.001
Table 4 Changes in pCa50
DpCa50 WT L29Q
Before/after cTnC-exchange ?0.06 ± 0.044 ?0.06 ± 0.030
Before/after cTnC-
exchange ? PPlc
-0.04 ± 0.030 -0.08 ± 0.030
PPlc, before/after PKA ?0.18 ± 0.004 ?0.20 ± 0.022
Table 4 summarizes the changes in pCa50 induced in skinned ﬁbers
(1.) by exchange with the recombinant hcTnCs (WT/L29Q), (2.) by
exchange with the recombinant cTnCs and additional treatment with
phosphatase, and (3.) the DpCa50 induced by incubation of the
phosphatase-treated, exchanged ﬁbers with PKA
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area of cTnC which has the potential to affect the activa-
tion properties of cTnC [4, 13, 28, 35], its functional effects
were investigated by several groups resulting in rather
divergent observations. However, none of the studies in
ﬁbers investigated whether this mutation blunts the
response to PKA as suggested by structural investigations
and observations with reconstituted proteins in solution [4,
13, 35]. We report here, that the mutation has no signiﬁcant
effect on Ca
2? sensitivity of contraction conﬁrming a
recent report [15]. More importantly, we show here for the
ﬁrst time, that the mutation does not interfere with the
PKA-induced decrease in Ca
2? sensitivity of contraction.
In addition, there was no effect on unloaded shortening of
skinned murine myocardium.
In ﬁbers not treated with phosphatase to dephosphory-
late sarcomeric PKA substrates or PKA to phosphorylate
them, hcTnC
L29Q had no signiﬁcant effect on the force–
pCa relation or on unloaded shortening velocity compared
to hcTnC
WT. This is in keeping with the observation of
Dweck et al. [15] who found no signiﬁcant changes in the
Ca
2? sensitivities of ATPase activity of reconstituted regu-
lated myoﬁlaments, of ATPase activity of cardiac myoﬁ-
brils, and of force of skinned porcine myocardium [15]. In
contrast, Liang et al. [28] reported an increase in pCa50 by
0.06 pCa units in skinned murine cardiomyocytes
exchanged with hcTnC
L29Q compared to hcTnC
WT at a
sarcomere length of 2.3 lm. Interestingly the Ca
2?-sensi-
tizing effect of the mutation increased to a difference in
pCa50 of 0.11 pCa units at a sarcomere length of 1.9 lm
[28]. It is not immediately apparent why in our hands and
in the study of Dweck et al. [15] the increase in Ca
2?
sensitivity is smaller or negligible compared to the inves-
tigation of Liang and co-workers [28]. Dweck investigated
the effects of the mutation in skinned porcine cardiac ﬁbers
and proposed that the difference between their results and
those of Liang possibly reﬂected the difference between
lower rodents and higher mammals. However, since we
like Liang et al. [28] used murine cardiac muscle, a species
difference most likely does not account for the observed
differences. In any case, our results in conjunction with
those of Dweck et al. [15] could well explain the rather
benign course of the disease in the patient who experienced
his ﬁrst HCM-related symptoms at the rather high age of
59 years [21].
In the study of Liang et al. [28], the enhanced Ca
2?
sensitivity of force correlated with an enhanced Ca
2?-
binding afﬁnity of cTnC
L29Q, measured as Ca
2?-dependent
changes in ﬂuorescence of isolated F27W-cTnCs [28]. As
an explanation it was proposed that (1) the L29Q mutation
may decrease the stability of the non-functional Ca
2?-
binding loop of cTnC which in turn impacts on the tran-
sition to the ‘‘open’’ conformation of the N-domain, and
(2) that the exposure of the hydrophobic surface, to which
the switch region of cTnI binds upon activation, is
increased by the L29Q mutation, which is important for
propagating the signal along the thin ﬁlament to release
inhibition of actomyosin interaction [28]. Dweck et al. [15]
also investigated Ca
2? binding to mutant and wild-type
cTnCs, reporting unclear ﬁndings towards hcTnC
L29Q. The
mutant cTnC induced a sensitization of Ca
2? binding to
the regulatory site in hcTnC
L29Q labeled only at Cys-84,
however, a desensitization of Ca
2? binding was observed
in double-labeled hcTnC
L29Q. Interestingly, the tendency
of isolated hcTnC
L29Q to induce a signiﬁcant change of
Ca
2? binding to the regulatory site was abolished when
hcTnC
L29Q was incorporated into regulated thin ﬁlaments
[15].
Since the L29Q substitution could also interfere with the
binding of cNTnC to the N-terminal arm of cTnI [4, 13,
35], a decrease in Ca
2? sensitivity could also be envi-
sioned. This is because binding of the N-terminal arm of
cTnI is required to stabilize the ‘‘open’’ conformation of
cNTnC [14, 27, 42]. The substitution of the non-polar with
a polar residue in the L29Q mutation interrupts binding of
the N-terminal cTnI peptide to a peptide derived from the
Leu-29 region of cTnC in a peptide array assay [35].
Likewise, this interaction is weakened by phosphorylation
of Ser23/24 of cTnI, causing a shift of the distribution of
the ‘‘open/closed’’ conformation of the N-domain towards
the latter [34]. In addition, phosphorylation of Ser23/24
accelerates the closing rate of cTnC induced by Ca
2?
dissociation [13]. Because the afﬁnity of the Ca
2?-bound
N-domain of cTnC
L29Q for the switch peptide (aa 147–163)
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123of cTnI was the same in the presence of the dephospho-
rylated or phosphorylated N-terminal arm of cTnI (residues
1–29), it was proposed that the impact of phosphorylation
was abolished [4].
After treatment with phosphatase, we observed an
increase in Ca
2? sensitivity in both, hcTnC
L29Q- and
hcTnC
WT-exchanged ﬁbers, whereby Ca
2? sensitivity,
although not statistically signiﬁcant, was somewhat higher
in hcTnC
L29Q- compared to hcTnC
WT-exchanged ﬁbers
(DpCa50 = 0.04 pCa units). These experiments suggest
that dephosphorylation of PKA substrates unmasks a Ca
2?-
sensitizing effect of the hcTnC
L29Q mutation. The PKA-
induced rightward shift of the force–pCa relation was not
affected by hcTnC
L29Q.
In contrast to the ﬁber studies [our study, 15, 28], which
found no change or an increase in Ca
2? sensitivity of force,
and in contrast to the ﬁndings of Dweck et al. [15], who
reported a non-signiﬁcant increase in the Ca
2? sensitivity
of ATPase activity of regulated thin ﬁlaments, Schmidt-
mann and colleagues [35], using a reconstituted system
with skeletal actin and tropomyosin together with cardiac
troponin, indeed reported that the mutation decreased the
Ca
2? sensitivity of actomyosin subfragment 1 (actoS1)-
ATPase activity and of sliding velocity of thin ﬁlaments in
an in vitro velocity assay by about 0.1 pCa units and
abolished the phosphorylation-induced decrease in Ca
2?
sensitivity. It should be noted that the mutation-induced
decrease in Ca
2? sensitivity was much smaller than that
induced by phosphorylation of cTnI [35]. In this system,
the mutation blunts the effect of PKA-induced Ca
2?
desensitization which may not be surprising based on the
peptide binding and NMR-studies [13, 35], which is in
contrast to the ﬁndings of the present study with skinned
myocardium. There are several possible explanations for
these divergent results:
First An important difference between in vitro assays as
in Schmidtmann et al. [35] and skinned myocardium is the
number of actin-myosin interactions which is load depen-
dent and low in in vitro ATPase and motility assays but
high under isometric conditions in ﬁbers. Thus, in the in
vitro assays Ca
2?-dependent activation of actomyosin
interaction is dominated by mechanisms intrinsic to the
thin ﬁlaments whereas in ﬁbers it is in addition inﬂuenced
by cooperative mechanisms of cross-bridge activation
(reviewed in [18]). The latter notion is supported by the
much higher cooperativity of pCa-force relations in the
present study (nH = 4.33-5.56) compared to Schmidtmann
et al.’s [35] pCa-ATPase relation (nH = 1.0–1.9) and pCa–
velocity relation (nH = 1.0–1.4). For this reason, in vitro
assays may be more sensitive to capture functional changes
resulting from altered TnI–TnC interactions which may be
blunted by additional, cross-bridge dependent mechanisms
in isometrically contracting ﬁbers. However, we note that
ﬁbers are closer to the physiological situation in the heart.
Second The protein composition of the reconstituted thin
ﬁlaments and the thin ﬁlaments in the ﬁbers differ. In the
reconstituted system, skeletal tropomyosin was used and
the system lacks cardiac myosin binding protein C
(cMyBP-C). While in assays with proteins in solution,
phosphorylation of Ser23/24 of cTnI is sufﬁcient to
decrease the Ca
2? sensitivity of contraction, recent experi-
ments with cMyBP-C null mice demonstrate that cMyBP-C
is required together with cTnI phosphorylation for PKA
effects on contractile parameters [5, 8]; however, it is not
known whether this requires the protein itself or its phos-
phorylation. Future experiments have to clarify the inter-
play between the L29Q mutation, cTnI phosphorylation
and cMyBP-C.
Mutation-induced effects in in vitro systems also appear
to be sensitive to the source of tropomyosin [11]a s
exempliﬁed by the cTnI G203S mutation. In one study [7],
this mutation induced a decrease in Ca
2? sensitivity of
isometric force without affecting sliding velocity of thin
ﬁlaments. In contrast, another study [23] reported a sig-
niﬁcant enhancement of the sliding velocity. A major
methodological difference is the use of human cardiac
tropomyosin [7] or tropomyosin prepared from rabbit
skeletal muscle [23]. Taken together, these results indicate
that the effect of a mutation seen in in vitro systems may
strongly depend not only on the experimental conditions
such as protein composition but also on pH and tempera-
ture, both of which have a signiﬁcant impact on the Ca
2?
activation of cTnC [17]. Differences in the protein com-
position (skeletal vs. cardiac) may also account for the
contradictory ﬁndings between the works of Schmidtmann
et al. [35] and of Dweck et al. [15].
To conclude, the effects on Ca
2? sensitivity induced by
hcTnC
L29Q are small to negligible compared to the alter-
ations in Ca
2? sensitivity observed with other HCM-linked
mutations of troponin subunits, and the magnitude and the
direction of the effect of the mutation—decrease or
increase or no change in Ca
2? sensitivity—appears to
depend on the experimental system. Furthermore, the
comparatively small changes in cTnC structure and inter-
action with cTnI are not reﬂected in altered contractile
parameters, conﬁrming other ﬁndings that switch kinetics
of troponin are modulated by the myoﬁlament lattice [37].
If hcTnC
L29Q does not alter Ca
2?-dependent force, how
can the development of HCM in the patient be explained?
The possibility remains that the mutation inﬂuences other
PKA-dependent parameters of Ca
2?-dependent force, such
as relaxation kinetics or tension cost. In fact, an impaired
energy homeostasis has been suggested to underlie the
hypertrophy in HCM [2]. A note of caution is warranted.
758 Basic Res Cardiol (2009) 104:751–760
123The mutation has only been described in one patient who
experienced ﬁrst HCM-related symptoms at the high age of
59 years [21]. The authors of the mutation report empha-
size that a familial incidence was not investigated and that
they could ‘‘not exclude that the mutation is simply a rare
polymorphism without any phenotypical relevance’’ [21].
Still, the mutation could be a de novo mutation. De novo
mutations of sarcomeric proteins have been reported [32].
It is for these cases which lack a familial background that
criteria need to be established for judging the potential
severity of a mutation. Future studies should show whether
skinned myocardium which allows to investigate the
functional effects of troponin mutations within the cardiac
sarcomere could be a building block in such a diagnostic
scheme. In any case, our results obtained in skinned murine
myocardium are consistent with the ﬁndings of Dweck
et al. [15] with skinned porcine myocardium, showing
consistency in cardiac preparations from two different
species. Together with the clinical data [21] a likely
explanation for the lack of effects is that the hcTnC
L29Q
mutation is a benign polymorphism accidentally found in
an HCM patient. Finally, it is puzzling that mutations in
cTnC are rare. Perhaps this reﬂects the key role of this
highly conserved molecule for cardiac function [17].
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